Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing

Chuikyo Drug Pricing Subcommittee on July 26 Towards the FY2024 drug pricing reform, the pharmaceutical industry is leaning on policymakers to scrap the so-called “spillover” rule under market expansion re-pricing. Given the need to maintain universal coverage, however, members of...read more